Husch Blackwell has a long track record in counseling those engaged in research and commercialization of novel—and controversial—therapies. We were one of the first large national law firms to establish a practice group devoted to cannabis, and as the utility and acceptance of psychedelic therapies have gained a foothold across the medical community, our firm is once again at the forefront in developing a multidisciplinary team to represent clients in this growing area of treatment.
Similar to the early days of the medical cannabis movement, psychedelic drugs such as MDMA, psilocybin, LSD, ketamine, and DMT are emerging in a complex and difficult legal and regulatory environment that can frustrate efforts to develop new therapies. Our team guides researchers, manufacturers, investors, clinicians, and other participants around and through the myriad obstacles that result from the patchwork of state and federal laws regulating Schedule I controlled substances, including the Controlled Substances Act (CSA), Money Laundering Control Act (MLCA), various criminal statutes that cover the sale and consumption of psychedelics, and various state legal and regulatory regimes.
Address & Contacts
300 S. Grand Ave., Suite 1500 Los Angeles, CA 90071